

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number
WO 2004/032910 A1

(51) International Patent Classification⁷: **A61K 31/05**,
47/34

(21) International Application Number:
PCT/KR2003/001690

(22) International Filing Date: 21 August 2003 (21.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2002-0061260 8 October 2002 (08.10.2002) KR

(71) Applicant: CENTURION, INC. [KR/KR]; 317, Goryu
Academytel, 437-3 Ahyun-dong, Mapo-gu, Seoul 121-861
(KR).

(71) Applicant and

(72) Inventor: JEE, Ung-Kil [KR/KR]; 1-303, Daelim Apt.,
57 Jamwon-dong, Seocho-gu, Seoul 137-907 (KR).

(74) Agent: HWANG, E-Nam; 507 New Seoul Bldg., 828-8
Yoksam-dong, Kangnam-gu, Seoul 135-080 (KR).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INJECTABLE 2,6-DIISOPROPYLPHENOL-CONTAINING ANESTHETIC COMPOSITION AND METHODS

(57) Abstract: An injectable anesthetic composition in a microemulsion phase is disclosed. The composition contains 2,6-diisopropylphenol as the active ingredient, together with polyethylene glycol 660 hydroxystearate, tetrahydrofurfuryl alcohol polyethyleneglycol ether, and an aqueous medium. Methods of making and using the injectable anesthetic composition are also disclosed.

WO 2004/032910 A1

INJECTABLE 2,6-DIISOPROPYLPHENOL-CONTAINING
ANESTHETIC COMPOSITION AND METHODS

5 TECHNICAL FIELD

This invention relates to a pharmaceutical composition, which is parenterally injectable in humans or animals, for inducing or maintaining anesthesia. More particularly, the invention relates to an injectable anesthetic composition in an aqueous phase comprising 2,6-diisopropylphenol (i.e., propofol) as an active ingredient.

10 BACKGROUND ART

2,6-Diisopropyl phenol, which is used as an anesthetic, has a lipophilic character and is thus able to easily penetrate the blood-brain barrier. Owing to its lipophilic character, 2,6-diisopropylphenol is water-insoluble, which has resulted in difficulty in developing a formulation for intravenous injection.

At present, an injectable formulation comprising propofol emulsified with soybean oil, phospholipid, and glycerin is commercially available from AstraZeneca. This injectable emulsion is problematic because its milky appearance makes it difficult to detect impurities with the naked eye. Further, the relatively large particle size ($>100 \text{ }\mu\text{m}$) can lead to formation of thrombi in capillaries and peripheral blood vessels.

20 U.S. Patent Nos. 4,056,635 and 4,798,846 disclose pharmaceutical compositions for general anesthesia, which are parenterally administrable to humans or animals, comprising a surfactant, such as CREMOPHOR EL or polysorbate 80 (TWEEN 80), and water-immiscible solvents, such as ethyl oleate or castor oil, and an additional solvent, such as ethanol,

polyethylene glycol, or propylene glycol. These pharmaceutical compositions, however, have significant drawbacks in terms of causing adverse effects, and hypersensitive responses against CREMOPHORS can be induced in animals or humans.

Use of polysorbate 80 as a surfactant is disclosed in International Publication No. WO97/10814, however, the problem of hypersensitivity is also found in anesthetics containing polysorbate 80.

Thus, while prior art propofol-containing products and methods of use thereof are known and are generally suitable for their limited purposes, they possess certain inherent deficiencies that detract from their overall utility for anesthesia. In view of the foregoing, it will be appreciated that providing an injectable propofol -containing anesthetic composition that is optically clear and does not produce a hypersensitive reaction would be a significant advancement in the art.

DISCLOSURE OF THE INVENTION

It is an advantage of the present invention to provide an injectable anesthetic composition that does not induce a hypersensitive reaction.

It is another advantage of the invention to provide an optically clear injectable anesthetic composition that facilitates the detection of impurities or foreign matter contained therein with the naked eye.

In an illustrative embodiment of the invention, an injectable anesthetic composition comprises a microemulsion comprising a mixture of 2,6-diisopropylphenol, polyethylene glycol 660 hydroxystearate, tetrahydrofurfuryl alcohol polyethyleneglycol ether, and an aqueous

medium. The composition can further comprise a surfactant selected from the group consisting of bile salts, lecithin, and mixtures thereof. Illustratively, the surfactant is present in an amount of about 0.1 to 0.5% by weight. In another illustrative embodiment of the invention, the aqueous medium comprises a tonicity adjustment agent in an amount sufficient to obtain an isotonic condition corresponding to blood plasma. Illustrative tonicity adjustment agents include trehalose, glucose, fructose, glycerol, sorbitol, mannitol, sucrose, xylitol, sodium chloride, and the like, and mixtures thereof. In certain illustrative embodiments of the invention, the composition comprises about 1 to 2% by weight of 2,6-diisopropylphenol, about 5 to 10% by weight of polyethylene glycol 660 hydroxystearate, about 10 to 25% by weight of tetrahydrofurfuryl alcohol polyethyleneglycol ether, and about 63-84% by weight of the aqueous medium.

Another illustrative embodiment of the invention relates to a method of making an injectable anesthetic composition comprising:

(a) mixing polyethylene glycol 660 hydroxystearate with the aqueous medium to result in an aqueous mixture and heating and then cooling the aqueous mixture to room temperature to result in an aqueous solution;

(b) adding 2,6-diisopropylphenol to tetrahydrofurfuryl alcohol polyethyleneglycol ether to result in an oil-phase mixture and heating and then cooling the oil-phase mixture to room temperature to result in an oil-phase solution;

(c) mixing the aqueous solution and the oil-phase solution with stirring to result in a stirred mixture; and

(d) heating the stirred mixture with additional stirring and then cooling to room

temperature to result in a microemulsion, thereby resulting in the injectable anesthetic composition.

Still another illustrative embodiment of the invention relates to a method for anesthetizing an animal or human comprising injecting the animal or human with an amount of an anesthetic composition effective for inducing or maintaining anesthesia, wherein the composition comprises a microemulsion comprising a mixture of 2,6-diisopropylphenol, polyethylene glycol 660 hydroxystearate, tetrahydrofurfuryl alcohol polyethyleneglycol ether, and an aqueous medium.

10 DETAILED DESCRIPTION OF THE INVENTION

Before the present injectable anesthetic composition and methods of making and methods of use thereof are disclosed and described, it is to be understood that this invention is not limited to the particular configurations, process steps, and materials disclosed herein as such configurations, process steps, and materials may vary somewhat. It is also to be understood that the terminology employed herein is used for the purpose of describing particular embodiments only and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims and equivalents thereof.

The publications and other reference materials referred to herein to describe the background of the invention and to provide additional details regarding its practice are hereby incorporated by reference. The references discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior

invention.

It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to an anesthetic composition comprising "a surfactant" includes a
5 mixture of one or more of such surfactants, reference to "an aqueous medium" includes reference to two or more of such aqueous media, and reference to "the thickening agent" includes reference to a mixture of two or more of such thickening agents.

In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.

10 As used herein, "comprising," "including," "containing," "characterized by," and grammatical equivalents thereof are inclusive or open-ended terms that do not exclude additional, unrecited elements or method steps. "Comprising" is to be interpreted as including the more restrictive terms "consisting of" and "consisting essentially of."

As used herein, "consisting of" and grammatical equivalents thereof exclude any element,
15 step, or ingredient not specified in the claim.

As used herein, "consisting essentially of" and grammatical equivalents thereof limit the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic or characteristics of the claimed invention.

As used herein, a "pharmaceutically acceptable" component is one that is suitable for use
20 with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or

a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.

As used herein, "aqueous medium" means a water-containing liquid, which may also contain salts, buffers, pH-adjusting agents, tonicity adjustment agents, and the like.

5 As used herein, "bile salts" are pharmaceutically acceptable salts of cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isoursodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, and the like, and mixtures thereof.

10 As used herein, "optically clear" and similar terms mean that the composition exhibits a transmittance at 660 nm of greater than about 90%, typically greater than about 94%, and more typically greater than about 97%.

As used herein, "PBS" means phosphate buffered saline, i.e., 0.01 M Na_2HPO_4 , 0.15 M NaCl, pH 7.2.

15 Since the anesthetic composition of the present invention is intended to be administered to a warm-blooded animal, including humans, the ingredients should be pharmaceutically acceptable for administration to animals and humans.

The present invention is directed to an injectable anesthetic composition comprising a microemulsion comprising 2,6-diisopropylphenol as an active ingredient and the hydrophilic
20 surfactant, polyethylene glycol 660 hydroxystearate (CAS No. 70142-34-6), and the cosurfactant and cosolvent, tetrahydrofurfuryl alcohol polyethyleneglycol ether (CAS No. 31692-85-0), wherein the microemulsion is formed by mixing these ingredients with an aqueous medium.

2,6-Diisopropylphenol, which is a widely used injectable anesthetic, is typically added to pharmaceutical compositions in an amount of about 1-2% by weight for use in general anesthesia. If 2,6-diisopropylphenol is added in an amount of less than about 1% by weight, sufficient anesthesia may not be achieved, in animal or human subjects. If the added amount of 2,6-diisopropylphenol exceeds about 2% by weight, then adverse effects may occur owing to overdosing of the anesthetic agent.

Used in the present invention as a surfactant, polyethylene glycol 660 hydroxystearate is commercially available as Solutol (BASF). For example, the product known as Solutol HS 15 is known and commercially available.

In an illustrative embodiment of the invention, the surfactant polyethylene glycol 660 hydroxystearate is illustratively contained in the injectable anesthetic agent in an amount of about 5-10% by weight, but its content is not limited to this range. That is, it is possible for the surfactant to be added in an amount of less than 5% or more than 10%. However, taking into consideration the range of content of the active ingredient, 2,6-diisopropylphenol, the content of the surfactant is typically greater than 5%. In addition, in the presence of 2,6-diisopropylphenol added in a maximum amount of about 2% by weight, the surfactant displays good solubility even when added in an amount of 10% by weight.

Another additive, tetrahydrofurfuryl alcohol polyethyleneglycol ether is also commercially available as Glycofurool (GF), which is exemplified as Glycofurool 75.

In a typical embodiment of the present invention, the cosurfactant and cosolvent, tetrahydrofurfuryl alcohol polyethylene glycol ether, which acts as an auxiliary agent for dissolution of the active ingredient, 1,6-diisopropylphenol, is contained in the injectable

anesthetic in an amount of about 10-25% by weight, but its content is not limited to this range. When the amounts of the active ingredient, 2,6-diisopropylphenol, and the major surfactant, polyethylene glycol 660 hydroxystearate, are within the ranges as described above, an amount of the auxiliary agent, tetrahydrofurfuryl alcohol polyethyleneglycol ether within the described
5 range is sufficient to obtain a clear injectable aqueous solution.

If desired, the injectable anesthetic agent according to the present invention can further include other surfactants, including a bile salt, such as sodium deoxycholate, and lecithin, and such selection of surfactants can be easily determined by one of ordinary skill in the art. Illustrative amounts of the bile salt and lecithin are in the range of about 0.1-0.5% by weight.

10 Dispersion medium, which is an aqueous medium, may be pharmaceutically acceptable distilled water for parenteral injection or an aqueous solution prepared by adding a suitable amount of a tonicity adjustment agent to distilled water to give an isotonic condition. To maintain the isotonic condition, osmolality is about 200-900 mOsmol/kg, and typically, about 260-390 mOsmol/kg. Examples of the tonicity adjustment agent may include trehalose, glucose,
15 fructose, glycerol, sorbitol, mannitol, sucrose, xylitol, sodium chloride, and the like, and mixtures thereof.

Besides the above ingredients, additives commonly used in the art may be used in the present invention. For example, the injectable anesthetic agent may include a liquid excipient, which is exemplified as ethanol, propylene glycol, glycerol, triethylene glycol, polyethylene
20 glycol, and mixtures thereof. Also, a pH regulator may be used to adjust the pH in the range of about 5.5 to about 9.5, and examples of pH regulators include citric acid, acetate, phosphoric acid, ascorbic acid, gluconic acid, succinic acid, tartaric acid, lactic acid, and the like, and salts

thereof, and mixtures thereof.

In addition, the injectable anesthetic agent may further include any of the following additives in a pharmaceutically acceptable amount: a thickening agent, an absorbent, a light stabilizer, a crystallization inhibitor, a complexing agent, an antioxidant, and an antiseptic.

5 Illustrative thickening agents include methylcellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, and mixtures thereof. Illustrative complexing agents include EDTA and salts thereof, phosphate, nitrate, acetate, citrate, and mixtures thereof. Illustrative antioxidants include ascorbic acid, sulfate compounds, L-cysteine, thiodipropionic acid, thiolactic acid, monothioglycerol, propyl galate, and mixtures
10 thereof. Illustrative antiseptics include methyl *p*-oxybenzoate, propyl *p*-oxybenzoate, PHB ester, chlorobutanol, benzyl alcohol, butanol, butane-1,3-diol, chlorohexidin salts, benzoic acid and its salts, sorbic acid, and mixtures thereof.

The injectable anesthetic agent of a microemulsion type comprising the above ingredients according to the present invention illustratively and typically has a particle size of about 15-35
15 nm.

In accordance with the present invention, there is provided a method of preparing such an injectable anesthetic composition containing 2,6-diisopropylphenol (generic name: propofol) as an active ingredient, which is homogeneously dispersed in an aqueous medium to give a clear emulsion, comprising (1) dissolving Solutol in an aqueous medium by adding it to distilled water
20 for parenteral injection or an aqueous solution containing a tonicity adjustment agent and heating, for example to 40-80°C or more typically 50-70°C, and then cooling the resulting mixture to room temperature to give an aqueous solution; (2) adding an effective amount of propofol to

GLYCOFUROL commonly used in an injectable preparation, heating to 40-80EC or more typically 50-70EC with stirring, and then cooling the resulting mixture to room temperature to give an oil-phase solution; (3) adding a suitable amount of the oil-phase solution into the aqueous solution at room temperature and then mixing the combination with stirring to allow reactions between the compounds; and (4) heating the reaction mixture again, illustratively at 40-80EC and more typically at 50-70EC with stirring, and then cooling to room temperature. Step 4 is usually repeated three or more times to produce a clear microemulsion.

Since a microemulsion is easily formed just by mixing with stirring according to the method of the present invention, the injectable anesthetic composition of a clear emulsion type according to the present invention can be simply prepared without use of high-cost equipment, such as a homogenizer or a microfluidizer, which are commonly used in the art.

The present invention will be explained in more detail with reference to the following examples in conjunction with the accompanying drawings. However, the following examples are provided only to illustrate the present invention, and the present invention is not limited by them.

As described above, the presently described injectable anesthetic composition does not induce hypersensitivity in animals or humans, and is optically clear, allowing detection of impurities with the naked eye, thus making it possible to prevent adverse effects from such impurities.

Example 1

First, 7.5 g of Solutol HS 15 (BASF) was added to 50 ml distilled water for parenteral

injection, and the mixture was heated at 60EC to dissolve Solutol HS in the aqueous medium, and the resulting mixture was then cooled to room temperature to give an aqueous solution. Separately, 15 g of Glycofurol 75 (commercially available from GF) was mixed with 1 g of propofol with heating, and the resulting mixture was then cooled to room temperature to give an oil-phase solution. The oil-phase solution was added to the water-phase solution little by little with stirring at room temperature. After the addition was ended, the mixture was well mixed with stirring at about 50 to 80EC, and then cooled to room temperature. The agitation at 50-80EC and cooling steps were performed three additional times, resulting in formation of a clear microemulsion.

Thereafter, about 26.5 ml of 1/15 M phosphate buffered saline (pH 7.4) was added to the microemulsion, thus giving 100 ml of a 1% injectable preparation, which contains propofol in an amount of 1% by weight.

Using conventional methods known in the art, the resulting injectable preparation was analyzed for optical clarity, pH, particle size, and zeta-potential, and the results are given in Table

1.

Example 2

To investigate the effects of the drug propofol on the physical and chemical properties of injectable preparations when the amount of propofol is increased, another injectable preparation was prepared according to the same procedure as in Example 1, except for addition of 1.1 g propofol, and production of an injectable preparation of total volume of 110 ml, by addition of 10 ml more distilled water.

Using conventional methods known in the art, the resulting injectable preparation was analyzed for optical clarity, pH, particle size, and zeta-potential, and the results are set out in Table 1.

5

Example 3

An injectable preparation was prepared according to the same procedure as in Example 1, except for use of a 10% dextrose solution as the aqueous medium.

Using conventional methods known in the art, the resulting injectable preparation was analyzed for optical clarity, pH, particle size, and zeta-potential, and the results are give in Table

10 1.

Example 4

An injectable preparation was prepared according to the same procedure as in Example 2, except for use of a 10% dextrose solution as an aqueous medium.

15

Using conventional methods known in the art, the resulting injectable preparation was analyzed for optical clarity, pH, particle size, and zeta-potential, and the results are give in Table 1.

| Table 1. Transmittance, pH, particle size, and zeta-potentials of injectable preparations in Examples 1 to 4. | | | | | |
|---|-------------------|--------|----|--------------------|---------------------|
| Preparation | Transmittance (%) | | pH | Particle size (nm) | Zeta-potential (mV) |
| | 540 nm | 660 nm | | | |

| | | | | | |
|-----------|-------|-------|------|------|-------------|
| Example 1 | 96.1 | 97.75 | 7.71 | 16.7 | -2.41--2.56 |
| Example 2 | 95.35 | 97.12 | 7.71 | 17.5 | -3.85--4.18 |
| Example 3 | 97.05 | 98.51 | 7.60 | 16.5 | -4.02--4.05 |
| Example 4 | 96.86 | 98.53 | 7.63 | 16.9 | -2.27--2.88 |

Examples 5-8

First, 7.5 g of Solutol HS 1 (BASF) was added to 50 ml of a 10% dextrose solution, and the mixture was heated to 50 to 80EC to dissolve the Solutol HS 15 in the aqueous medium. The resulting mixture was then cooled to room temperature to give an aqueous solution. Separately, 15 g of Glycofurol 75 (GF) was mixed with 250 mg of a bile salt (sodium deoxycholate) and 500 mg of 99% egg lecithin, and the mixture was heated at 50-80EC to dissolve the ingredients. Next, 1 g (Example 5), 1.1 g(Example 6), 1.2 g (Example 7), or 1.3 g (Example 8) of propofol was added to the resulting mixture and dissolved completely, thus giving an oil-phase solution. The oil-phase solution was added to the aqueous solution little by little with stirring at room temperature, and the resulting mixture was heated at 60EC for 5 minutes with agitation and then cooled to room temperature. The agitation at 60EC and cooling steps were repeated three more times, resulting information of a clear microemulsion.

Thereafter, 25 ml of 1/15 M phosphate buffered saline (pH 7.4) was added to the microemulsion, thus giving a 1% injectable preparation, to which an aqueous medium was added according to intended use.

Using conventional methods known in the art, the resulting injectable preparation was analyzed for optical clarity and particle size, and the results are give in Table 2.

Examples 9-12

Injectable preparations of Examples 9 to 12 were prepared according to the same procedure as in Examples 5-8, except for use of a 20% trehalose solution as an aqueous medium.

5 Using conventional methods known in the art, the resulting injectable preparation was analyzed for optical clarity and particle size, and the results are given in Table 2.

Examples 13-16

10 Injectable preparations of Examples 13 to 16 were prepared according to the same procedure as Examples 5-8, except for use of 10 ml of a 10% trehalose solution as aqueous medium.

Using conventional methods known in the art, the resulting injectable preparation was analyzed for optical clarity and particle size, and the results are given in Table 2.

| Table 2. Optical clarity and particle sizes of injectable preparations of Examples 5-16 | | |
|---|-------------------------------|--------------------|
| Injectable Preparation | Optical clarity (% at 660 nm) | Particle size (nm) |
| Example 5 | 99.16 | 26.2 |
| Example 6 | 98.95 | 25.5 |
| Example 7 | 99.38 | 24.6 |
| Example 8 | 98.75 | 26.0 |
| Example 9 | 100.00 | 33.6 |

| | | |
|------------|-------|------|
| Example 10 | 99.83 | 34.3 |
| Example 11 | 99.74 | 29.7 |
| Example 12 | 99.03 | 34.2 |
| Example 13 | 98.71 | 29.1 |
| Example 14 | 99.57 | 27.6 |
| Example 15 | 98.92 | 25.2 |
| Example 16 | 99.14 | 25.6 |

Example 17-19

According to Table 3, phosphate buffered saline (pH 7.4) was used as an aqueous medium in Example 17, a 10% trehalose solution was used in Example 18, and distilled water for injection was used in Example 19. An oil-phase solution in each of Experiments 17-19 was prepared according to the procedure of Example 7. A 1% injectable preparation in each of Examples 17-19 was prepared according to the procedure of Example 1 except that a final volume of 120 ml was obtained.

| Table 3. Compositions of injectable preparations of Examples 17 to 19 | | | |
|---|-----------------|---------------------|-----------------------|
| | Example 17 | Example 18 | Example 19 |
| Aqueous solutions | 50 ml PBS | 50 ml 10% trehalose | 50 ml distilled water |
| | 7.5 g Solutol | 7.5 g Solutol | 7.5 g Solutol |
| Oil-phase solutions | 15 g Glycofurol | 15 g Glycofurol | 15 g Glycofurol |

| | | | |
|--------------|-------------------------|-------------------------|-------------------------|
| | 250 mg SDC | 250 mg SDC | 250 mg SDC |
| | 500 mg 99% egg lecithin | 500 mg 99% egg lecithin | 500 mg 99% egg lecithin |
| | 1.2 g propofol | 1.2 g propofol | 1.2 g propofol |
| PBS | q.s. | q.s. | q.s. |
| Total Volume | 120 ml | 120 ml | 120 ml |

Using conventional methods known in the art, the resulting injectable preparations were analyzed for pH, optical clarity, viscosity, and particle size, and the results are given in Table 4.

| Table 4 | | | | |
|------------------------|-----|-------------------------------|----------------|--------------------|
| Injectable Preparation | pH | Optical Clarity at 660 nm (%) | Viscosity (cp) | Particle size (nm) |
| Example 17 | 7.6 | 98.7 | 0.8747 | 26.5 |
| Example 18 | 7.4 | 97.9 | 0.8764 | 27.1 |
| Example 19 | 7.5 | 99.0 | 0.8705 | 23.2 |

5

Example 20

According to Table 5, a dextrose solution was used as an aqueous medium instead of trehalose solution, and an oil-phase solution was prepared by reducing an amount of egg lecithin to 250 mg and adding 1.1 g of the drug propofol. In each Example, a 1% injectable preparation was formulated according to procedure of Example 1 except that a final volume of 110 ml was obtained.

10

Table 5. Compositions of injectable preparations

| | Example 17 | Example 18 | Example 19 |
|---------------------|-------------------------|-------------------------|-------------------------|
| Aqueous solutions | 50 ml distilled water | 50 ml 10% dextrose | 50 ml 10% dextrose |
| | 7.5 g Solutol | 7.5 g Solutol | 7.5 g Solutol |
| Oil-phase solutions | 15 g Glycofurol | 15 g Glycofurol | 15 g Glycofurol |
| | 250 mg SDC | 250 mg SDC | 250 mg SDC |
| | 250 mg 99% egg lecithin | 250 mg 99% egg lecithin | 250 mg 99% egg lecithin |
| | 1.1 g propofol | 1.1 g propofol | 1.1 g propofol |
| PBS | q.s. | q.s. | q.s. |
| Total Volume | 110 ml | 110 ml | 110 ml |

Using conventional methods known in the art, the resulting injectable preparations were analyzed for pH and optical clarity, and the results are give in Table 6.

| Table 6 | | |
|------------------------|-----|-------------------------------|
| Injectable Preparation | pH | Optical Clarity at 660 nm (%) |
| Example 17 | 7.5 | 96.04 |
| Example 18 | 6.7 | 94.93 |
| Example 19 | 6.9 | 97.24 |

5

Experimental Example 1

Test for an anesthetic effect of the injectable preparation. The injectable preparation of

Example 5 was compared with the oil-based emulsion DIPRIVAN in terms of anesthetic effect according to their administered amounts, as well as on blood pressure and respiration in rabbits. Three rabbits of about 3 kg of body weight were used in each case. After immobilizing rabbits on a fixed board, a 24-ga. venous catheter was inserted into the ear vein, and an anesthetic agent was injected into the ear vein through the catheter. After recording baseline levels of the venous pressure at the rabbit ear, the anesthetic agent was injected at a rate of 1 ml/kg/hr. After 10 minutes, the venous pressure at the rabbit ear was again recorded. Thereafter, the injected amount of the anesthetic agent was increased to 2 ml/kg/hr, 4 ml/kg/hr, 6 ml/kg/hr, 8 ml/kg/hr, and 10 ml/kg/hr at intervals of 10 minutes.

The anesthetic effect of the treatment was evaluated by inserting a 24-gauge arterial catheter into the ear artery, and the arterial pressure at the rabbit ear was measured. Induction of anesthesia in rabbits was evaluated by stimulating the cornea with gauze, or investigating response of the end of the rabbit's nose upon being pricked with a needle, which is the so-called pinprick stimulation method.

The results are give in Tables 7 and 8.

| Table 7. Effect of the injectable preparation of Example 5 on induction of anesthesia in rabbits. | | | | | | | | |
|---|------------|----------|----------------------|-------|-------|-------|-------|-------|
| | Rabbit No. | Baseline | Dose rate (ml/kg/hr) | | | | | |
| | | | 1 | 2 | 4 | 6 | 8 | 10 |
| BP (S/D) | 1 | 105/70 | 105/71 | 95/70 | 79/61 | 73/61 | 61/47 | 68/48 |
| | 2 | 100/65 | 94/61 | 89/60 | 80/70 | 74/65 | 71/62 | 69/58 |

| | 3 | 100/70 | 92/64 | 90/65 | 87/65 | 107/83 | 87/62 | 83/53 |
|---------------------------|---|--------|-------|-------|-------|--------|-------|-------|
| Stimulation of the cornea | 1 | +++ | +++ | +++ | + | + | + | + |
| | 2 | +++ | +++ | +++ | ++ | + | + | + |
| | 3 | +++ | +++ | +++ | ++ | ++ | + | + |
| Pinprick stimulation | 1 | +++ | +++ | +++ | + | + | + | + |
| | 2 | +++ | +++ | +++ | ++ | + | + | + |
| | 3 | +++ | +++ | +++ | ++ | + | ∇ | - |
| Difficulty in breathing | 1 | - | - | - | - | - | - | + |
| | 2 | - | - | - | - | - | - | - |
| | 3 | - | - | - | - | - | - | - |

Table 8. Effect of DIPRIVAN on induction of anesthesia in rabbits

| | Rabbit No. | Baseline | Dose rate (ml/kg/hr) | | | | | |
|---------------------------|------------|----------|----------------------|-------|-------|-------|-------------------|-------|
| | | | 1 | 2 | 4 | 6 | 8 | 10 |
| BP (S/D) | 4 | 79/61 | 82/65 | 83/64 | 65/52 | 84/63 | 84/60 | 81/61 |
| | 5 | 100/66 | 110/69 | 92/70 | 85/73 | 82/66 | anes- thetized | death |
| | 6 | 91/63 | 85/63 | 83/60 | 60/54 | 63/57 | 70/59 | 70/59 |
| Stimulation of the cornea | 4 | +++ | +++ | +++ | +++ | + | + | ∇ |
| | 5 | +++ | +++ | +++ | +++ | +++ | - | - |
| | 6 | +++ | +++ | ++ | + | + | + | ∇ |
| Pinprick stimula- | 4 | +++ | +++ | +++ | ++ | + | + | ∇ |

| | | | | | | | | |
|-------------------------------|---|-----|-----|-----|-----|-----|---|-------|
| | 5 | +++ | +++ | +++ | +++ | +++ | - | - |
| | 6 | +++ | +++ | ++ | + | + | + | ∇ |
| Difficulty in breathing | 4 | - | - | - | - | - | - | - |
| | 5 | - | - | - | - | - | - | death |
| | 6 | - | - | - | - | - | - | - |

As is apparent from the data in Tables 7 and 8, the injectable preparation of Example 5 has an anesthetic effect similar to that of DIPRIVAN.

5

Experimental Example 2

Assay for stability of the injectable formulations of Examples 5 to 16. After being kept in cold storage for 90 days, the injectable preparations of Examples 5 to 16 were analyzed for stability using HPLC. The pump was a Waters model 510, and the detector was a Waters model 486. The column was an Intersil ODS 3.5 Φ m, 4.6 x 250 mm from GL Science. The mobile
10 phase was acetonitrile:water:acetic acid (pH 2.0) in a ratio of 70:30:0.1. The sample size injected was 50 Φ l, and fractionation was carried out at a flow rate of 1.2 ml/min. Detection was at 276 nm.

The results of these HPLC assays showed that all of the formulations had stabilities in the range of 98 to 100%.

15

CLAIMS

1. An injectable anesthetic composition comprising a microemulsion comprising a mixture of 2,6-diisopropylphenol, polyethylene glycol 660 hydroxystearate, tetrahydrofurfuryl alcohol polyethyleneglycol ether, and an aqueous medium.

5

2. The composition of claim 1 further comprising a surfactant selected from the group consisting of bile salts, lecithin, and mixtures thereof.

3. The composition of 2 wherein the composition comprises about 0.1 to 0.5% by weight of the surfactant.

10

4. The composition of claim 2 wherein the surfactant is a bile salt selected from the group consisting of pharmaceutically acceptable salts of cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isoursodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, and mixtures thereof.

15

5. The composition of claim 1 further comprising a bile salt.

20

6. The composition of claim 5 wherein the composition comprises about 0.1 to 0.5% by weight of the bile salt.

7. The composition of claim 5 wherein the bile salt is a member selected from the group consisting of pharmaceutically acceptable salts of cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isoursodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, and mixtures thereof.

8. The composition of claim 1 further comprising lecithin.

9. The composition of claim 8 wherein the composition comprises about 0.1 to 0.5% by weight of the lecithin.

10. The composition of claim 1 further comprising a mixture of a bile salt and lecithin.

11. The composition of claim 10 wherein the composition comprises about 0.1 to 0.5% by weight of the mixture of a bile salt and lecithin.

12. The composition of claim 10 wherein the bile salt is a member selected from the group consisting of pharmaceutically acceptable salts of cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isoursodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid,

glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, and mixtures thereof.

13. The composition of claim 1 wherein the aqueous medium comprises a tonicity
5 adjustment agent in an amount sufficient to obtain an isotonic condition corresponding to blood plasma.

14. The composition of claim 13 wherein the tonicity adjustment agent is a member
selected from the group consisting of trehalose, glucose, fructose, glycerol, sorbitol, mannitol,
10 sucrose, xylitol, sodium chloride, and mixtures thereof.

15. The composition of claim 1 wherein the composition comprises about 1 to 2% by
weight of 2,6-diisopropylphenol.

16. The composition of claim 1 wherein the composition comprises about 5 to 10%
15 by weight of polyethylene glycol 660 hydroxystearate.

17. The composition of claim 1 wherein the composition comprises about 10 to 25%
by weight of tetrahydrofurfuryl alcohol polyethyleneglycol ether.

18. The composition of claim 1 further comprising a member selected from the group
20 consisting of liquid excipients, pH regulators, thickening agents, absorbents, light stabilizers,

crystallization inhibitors, complexing agents, antioxidants, antiseptics, and mixtures thereof.

19. The composition of claim 18 wherein the composition comprises a liquid
excipient selected from the group consisting of ethanol, propylene glycol, glycerol, triethylene
5 glycol, polyethylene glycol, and mixtures thereof.

20. The composition of claim 18 wherein the composition comprises a pH regulator
selected from the group consisting of citric acid, acetate, phosphoric acid, ascorbic acid, gluconic
acid, succinic acid, tartaric acid, lactic acid, and salts thereof, and mixtures thereof.

21. The composition of claim 18 wherein the composition comprises a thickening
agent selected from the group consisting of methylcellulose, hydroxyethyl cellulose, sodium
carboxymethyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, and mixtures thereof.

22. The composition of claim 18 wherein the composition comprises a complexing
agent selected from the group consisting of EDTA and salts thereof, phosphate, nitrate, acetate,
citrate, and mixtures thereof.

23. The composition of claim 18 wherein the composition comprises an antioxidant
selected from the group consisting of ascorbic acid, sulfate compounds, L-cysteine,
thiodipropionic acid, thiolactic acid, monothioglycerol, propyl galate, and mixtures thereof.

24. The composition of claim 18 wherein the composition comprises an antiseptic selected from the group consisting of methyl *p*-oxybenzoate, propyl *p*-oxybenzoate, PHB ester, chlorobutanol, benzyl alcohol, butanol, butane-1,3-diol, chlorohexidin salts, benzoic acid and its salts, sorbic acid, and mixtures thereof.

5

25. The composition of claim 1 wherein the composition exhibits a transmittance at 660 nm of greater than about 90%.

26. A method of making an injectable anesthetic composition comprising:

10

(a) mixing polyethylene glycol 660 hydroxystearate with an aqueous medium to result in an aqueous mixture and heating and then cooling the aqueous mixture to room temperature to result in an aqueous solution;

(b) adding 2,6-diisopropylphenol to tetrahydrofurfuryl alcohol polyethyleneglycol ether to result in an oil-phase mixture and heating and then cooling the oil-phase mixture to room temperature to result in an oil-phase solution;

15

(c) mixing the aqueous solution and the oil-phase solution with stirring to result in a stirred mixture; and

(d) heating the stirred mixture with additional stirring and then cooling to room temperature to result in a microemulsion, thereby resulting in the injectable anesthetic composition.

20

27. The method of claim 26 wherein the aqueous medium comprises a tonicity adjustment agent selected from the group consisting of trehalose, glucose, fructose, glycerol,

sorbitol, mannitol, sucrose, xylitol, sodium chloride, and mixtures thereof.

28. The method of claim 26 wherein the aqueous medium comprises a surfactant selected from the group consisting of bile salts, lecithin, and mixtures thereof.

5

29. The method of claim 28 wherein the surfactant is a bile salt selected from the group consisting of pharmaceutically acceptable salts of cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isoursodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, and mixtures thereof.

10

30. The method of claim 26 wherein the aqueous medium comprises a pH regulator selected from the group consisting of citric acid, acetate, phosphoric acid, ascorbic acid, gluconic acid, succinic acid, tartaric acid, lactic acid, and salts thereof, and mixtures thereof.

15

31. The method of claim 26 wherein the aqueous medium comprises a thickening agent selected from the group consisting of methylcellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, and mixtures thereof.

20

32. The method of claim 26 wherein the aqueous medium comprises a complexing agent selected from the group consisting of EDTA and salts thereof, phosphate, nitrate, acetate,

citrate, and mixtures thereof.

33. The method of claim 26 wherein the aqueous medium comprises an antioxidant selected from the group consisting of ascorbic acid, sulfate compounds, L-cysteine, 5 thiodipropionic acid, thiolactic acid, monothioglycerol, propyl galate, and mixtures thereof.

34. The method of claim 26 wherein the aqueous medium comprises an antiseptic selected from the group consisting of methyl *p*-oxybenzoate, propyl *p*-oxybenzoate, PHB ester, chlorobutanol, benzyl alcohol, butanol, butane-1,3-diol, chlorohexidin salts, benzoic acid and its 10 salts, sorbic acid, and mixtures thereof.

35. The method of claim 26 wherein heating of the aqueous mixture, the oil-phase mixture, and the stirred mixture is carried out at 40-80EC.

15 36. A method for anesthetizing an animal or human comprising injecting the animal or human with an amount of an anesthetic composition effective for inducing or maintaining anesthesia, wherein the composition comprises a microemulsion comprising a mixture of 2,6-diisopropylphenol, polyethylene glycol 660 hydroxystearate, tetrahydrofurfuryl alcohol polyethyleneglycol ether, and an aqueous medium.

20

37. The method of claim 36 wherein the composition further comprises a surfactant selected from the group consisting of bile salts, lecithin, and mixtures thereof.

38. The method of 37 wherein the composition comprises about 0.1 to 0.5% by weight of the surfactant.

5 39. The method of claim 37 wherein the surfactant is a bile salt selected from the group consisting of pharmaceutically acceptable salts of cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isoursodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid,
10 hyodeoxycholic acid, and mixtures thereof.

40. The method of claim 36 wherein the composition further comprises a bile salt.

41. The method of claim 40 wherein the composition comprises about 0.1 to 0.5% by
15 weight of the bile salt.

42. The method of claim 40 wherein the bile salt is a member selected from the group consisting of pharmaceutically acceptable salts of cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid,
20 isoursodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, and mixtures thereof.

43. The method of claim 36 wherein the composition further comprises lecithin.

44. The method of claim 43 wherein the composition comprises about 0.1 to 0.5% by
5 weight of the lecithin.

45. The method of claim 36 wherein the composition further comprises a mixture of a
bile salt and lecithin.

10 46. The method of claim 45 wherein the composition comprises about 0.1 to 0.5% by
weight of the mixture of a bile salt and lecithin.

47. The method of claim 45 wherein the bile salt is a member selected from the group
consisting of pharmaceutically acceptable salts of cholic acid, deoxycholic acid,
15 chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid,
isoursodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid,
glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid,
hyodeoxycholic acid, and mixtures thereof.

20 48. The method of claim 36 wherein the aqueous medium comprises a tonicity
adjustment agent in an amount sufficient to obtain an isotonic condition corresponding to blood
plasma.

49. The method of claim 48 wherein the tonicity adjustment agent is a member selected from the group consisting of trehalose, glucose, fructose, glycerol, sorbitol, mannitol, sucrose, xylitol, sodium chloride, and mixtures thereof.

5

50. The method of claim 36 wherein the composition comprises about 1 to 2% by weight of 2,6-diisopropylphenol.

51. The method of claim 36 wherein the composition comprises about 5 to 10% by weight of polyethylene glycol 660 hydroxystearate.

10

52. The method of claim 36 wherein the composition comprises about 10 to 25% by weight of tetrahydrofurfuryl alcohol polyethyleneglycol ether.

53. The method of claim 36 further comprising a member selected from the group consisting of liquid excipients, pH regulators, thickening agents, absorbents, light stabilizers, crystallization inhibitors, complexing agents, antioxidants, antiseptics, and mixtures thereof.

15

54. The method of claim 53 wherein the composition comprises a liquid excipient selected from the group consisting of ethanol, propylene glycol, glycerol, triethylene glycol, polyethylene glycol, and mixtures thereof.

20

55. The method of claim 53 wherein the composition comprises a pH regulator selected from the group consisting of citric acid, acetate, phosphoric acid, ascorbic acid, gluconic acid, succinic acid, tartaric acid, lactic acid, and salts thereof, and mixtures thereof.

5 56. The method of claim 53 wherein the composition comprises a thickening agent selected from the group consisting of methylcellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, and mixtures thereof.

57. The method of claim 53 wherein the composition comprises a complexing agent
10 selected from the group consisting of EDTA and salts thereof, phosphate, nitrate, acetate, citrate, and mixtures thereof.

58. The method of claim 53 wherein the composition comprises an antioxidant selected from the group consisting of ascorbic acid, sulfate compounds, L-cysteine,
15 thiodipropionic acid, thiolactic acid, monothioglycerol, propyl galate, and mixtures thereof.

59. The method of claim 53 wherein the composition comprises an antiseptic selected from the group consisting of methyl *p*-oxybenzoate, propyl *p*-oxybenzoate, PHB ester, chlorobutanol, benzyl alcohol, butanol, butane-1,3-diol, chlorohexidin salts, benzoic acid and its
20 salts, sorbic acid, and mixtures thereof.

60. The method of claim 36 wherein the composition exhibits a transmittance at 660 nm of greater than about 90%.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 03/01690-0

CLASSIFICATION OF SUBJECT MATTER

IPC⁷: A61K 31/05, 47/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS, WPI, EPODOC, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|---|---------------------------|
| A | WO 00/78301 A1 (KUHNIL PHARM. CO., LTD) 28 December 2000 (28.12.00) <i>claims.</i> | 1-12, 14-24, 26-47, 49-59 |
| A | WO 00/59475 A1 (LIPOCINE INC.) 12 October 2000 (12.10.00) <i>claims 1, 3, 5, 46, 51, 64.</i> | 1-12, 14-24, 26-47, 49-59 |
| A | KR 2001055736 A (FDL INC.) 4 July 2001 (04.07.01) <i>abstract (WPI).</i> | 1-12, 14-24, 26-47, 49-59 |
| A | WO 02/09671 A2 (UNIV. FLORIDA) 7 February 2002 (07.02.02) <i>claims.</i> | 1-12, 14-24, 26-47, 49-59 |

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„B“ earlier application or patent but published on or after the international filing date

„L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„I“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„E“ document member of the same patent family

Date of the actual completion of the international search

3 November 2003 (03.11.2003)

Date of mailing of the international search report

25 November 2003 (25.11.2003)

Name and mailing address of the ISA/AT

Austrian Patent Office

Dresdner Straße 87, A-1200 Vienna

Facsimile No. 1/53424/535

Form PCT/ISA/210 (second sheet) (July 1998)

Authorized officer

KRENN M.

Telephone No. 1/53424/435

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 03/01690-0

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 36-60
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 36-60 are directed to a therapeutic method of treatment of the human/animal body, the search has been carried out and is based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 13,25,48,60
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The formulations "...in an amount sufficient to obtain an isotonic condition.." (claims 13,48) and "...composition exhibits a transmittance at 660 nm of greater than about 90%." (claims 25,60) are functionally orientated.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 03/01690-0

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|----------------|---------------------|----------------------------|---------------------|
| KR A | 20010557 36 | | none | |
| WO A | 059475 | | none | |
| WO A | 078301 | | none | |
| WO A | 9671 | | none | |